FDA
-
-
-
-
-
-
-
Cardiol Therapeutics surpasses 50% enrollment in phase III trial
-
-
-
-
-
-
-
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
-
-
-
-
-
-
-
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
-
-
-
-
-
-
-
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference
-
-
-
-
-
-
-
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors
-
-
-
-
-
-
-
Cardiol Therapeutics (CRDL) Announces Publication of Research in the Journal of the American College of Cardiology
-
-
-
-
-
-
-
Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis
-
322,090 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

